Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20128492 | 1.00 | NPC1 (0.43) | NPC1CYP2C19ALDH1A1MAPTHTT | |
| SCHEMBL16774770 | 0.90 | NPC1 (0.44) | NPC1CYP2C19ALDH1A1MAPTHTT | |
| SCHEMBL16774864 | 0.90 | NPC1 (0.44) | NPC1CYP2C19ALDH1A1MAPTHTT | |
| SCHEMBL20132829 | 0.86 | HPRT1 (0.42) | NPC1CYP2C19ALDH1A1MAPTHTT | |
| SCHEMBL20132791 | 0.86 | HPRT1 (0.42) | NPC1CYP2C19ALDH1A1MAPTHTT | |
| SCHEMBL16774481 | 0.81 | KMT2A (0.44) | NPC1CYP2C19MAPTHTTSMN1; SMN2 | |
| SCHEMBL19732965 | 0.81 | KMT2A (0.44) | NPC1CYP2C19MAPTHTTSMN1; SMN2 | |
| SCHEMBL20128491 | 0.80 | CTSB (0.43) | NPC1CYP2C19ALDH1A1MAPTHTT | |
| SCHEMBL20128499 | 0.80 | CTSB (0.43) | NPC1CYP2C19ALDH1A1MAPTHTT | |
| SCHEMBL20132789 | 0.79 | TDP1 (0.43) | NPC1SMN1; SMN2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040760-B2 | Pyrrolidine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-08-07 | — | — | US | disclosed |
| US-20180127364-A1 | PYRROLIDINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127364-A1 | PYRROLIDINE COMPOUND | CAT, POLI, PPOX | NPC1 2417/4885CYP2C19 498/4885ALDH1A1 783/4885 |
| US-10040760-B2 | Pyrrolidine compound | CAT, POLI, PPOX | NPC1 2417/4885CYP2C19 498/4885ALDH1A1 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.